NCT06926829 - A Long-term Trial of EB-1020 in Adult Patients With ADHD | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG

EB-1020 (Centanafadine) 164.4 mg

164.4 mg, capsule, oral, once daily, for 52 weeks

DRUG

EB-1020 (Centanafadine) 328.8 mg

328.8 mg, capsule, oral, once daily, for 52 weeks

Trial Locations (1)

RECRUITING

Maynds Tower Mental Clinic, Tokyo